September 12, 2024 – Oncopeptalks on South Korea, growth and pipeline – David and Sofia discusses the recent announcement on South Korea as well as some questions following the recent Q2 report presentation.
May 22, 2024 – Sofia Heigis talks about her visit to Spain to raise awareness of the company’s launch there. She and David also talk about the company’s recent share issue and some thoughts on the upcoming quarterly report and annual general meeting.
April 4, 2024 – Sofia Heigis, CEO, and David Augustsson, Head of IR, discusses the recent announcement of net sales for the first quarter and collaboration with Vector Pharma to commercialize Oncopeptides’ flagship drug Pepaxti in the Middle East and North Africa (MENA) region.
February 27, 2024 – In this episode Jakob Lindberg, Chief Scientific Officer discusses the recent decision by the U.S. Food and Drug Administration to reconfirm the withdrawal of Pepaxto in a conversation with David Augustsson, Head of IR and Communication. Topics covered are the journey from U.S. approval to withdrawal for Pepaxto, his view on the recent decision and next, if any, steps in the USA for the drug.
December 20, 2023 – End of year discussion where Sofia Heigis and David Augustsson cover topics such as when we can expect a decision regarding Oncopeptides’ appeal in the U.S., sales in Europe in 2024 and beyond as well as share some highlights from this year’s ASH meeting in San Diego.
October 20, 2023 – In this edition, we focus on medical congresses and their importance for the marketing and sales of drugs. Sofia Heigis, CEO of Oncopeptides, joins to give her take on some of the key events in the world of multiple myeloma.
September 20, 2023 – Oncopeptalks 1st edition – Fireside chat with CEO Sofia Heigis. She talks about some recent news for the company, including the decision by the CHMP to recommend an extension into earlier lines, what factors play into a next decision following that, the status of sales in Europe and the FDA appeal. Relatively fresh in her new role as CEO, she also shares her personal story on why she joined the company and what motivates her.
Read more
October 11, 2024 – In the latest episode of Oncopeptalks, Sofia meets with Patrick Jordan, who is visiting Stockholm, to discuss the partnership between his organization and Oncopeptides, who does what in the cooperation, and the timeline for sales. Before this, David and Sofia discuss the recently recognized European Multiple Myeloma Day and its importance for the multiple myeloma community.
June 27, 2024 – Oncopeptalks on congresses and CD selection – Sofia talks to Denise about the journey Oncopeptides has taken and how its congress presence and perception has changed over the last two years and also Sofia’s prospective of the first drug candidate from the SPiKE platform.
April 25, 2024 – we meet with Cristina Bando, Spanish Country Manager at Oncopeptides who visits David Augustsson, Head of IR and Communications, in Stockholm for a short conversation on herself, the process of gaining market access in Spain and future of Pepaxti in Spain.
March 13, 2024 – Listen to Sofia Heigis, CEO, and Henrik Bergentoft, CFO, talk about why Oncopeptides is carrying out a new share issue, where the money will go, what a rights issue really is and what you as a current or potential shareholder should think about.
January 29, 2024 – CEO Sofia Heigis deep dives into the rapidly changing treatment landscape for multiple myeloma and where Pepaxti is positioned versus its competitors.
November 15, 2023 – We meet with Oncopeptides CEO Sofia Heigis to address some of the questions and comments we have received following the November 8 Q3 report and presentation.
September 28, 2023 – Interview with CEO Sofia Heigis about the news that Oncopeptides opts to abandon Type II variation process for Pepaxti, and Price negotiations in Germany.
Read the press release and the Q&A for investors
